Precision BioSciences, Inc. (DTIL)
NASDAQ: DTIL · Real-Time Price · USD
5.02
0.00 (0.00%)
At close: Dec 5, 2025, 4:00 PM EST
5.01
-0.01 (-0.30%)
After-hours: Dec 5, 2025, 4:10 PM EST
Precision BioSciences Revenue
Precision BioSciences had revenue of $13.00K in the quarter ending September 30, 2025, a decrease of -97.74%. This brings the company's revenue in the last twelve months to $698.00K, down -99.07% year-over-year. In the year 2024, Precision BioSciences had annual revenue of $68.70M with 40.98% growth.
Revenue (ttm)
$698.00K
Revenue Growth
-99.07%
P/S Ratio
72.27
Revenue / Employee
$6,463
Employees
108
Market Cap
120.84M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 68.70M | 19.97M | 40.98% |
| Dec 31, 2023 | 48.73M | 23.63M | 94.15% |
| Dec 31, 2022 | 25.10M | -90.43M | -78.28% |
| Dec 31, 2021 | 115.53M | 91.24M | 375.72% |
| Dec 31, 2020 | 24.29M | 2.05M | 9.20% |
| Dec 31, 2019 | 22.24M | 11.36M | 104.34% |
| Dec 31, 2018 | 10.88M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 435.16B |
| Johnson & Johnson | 92.15B |
| Merck & Co. | 64.24B |
| AbbVie | 59.64B |
| Eli Lilly and Company | 59.42B |
| AstraZeneca | 58.13B |
| Novartis AG | 56.37B |
| Novo Nordisk | 49.58B |
DTIL News
- 1 day ago - Precision Biosciences: Still Swinging And Finally Drawing Blood - Seeking Alpha
- 16 days ago - Precision BioSciences Announces Presentation of Clinical Data from the ELIMINATE-B Trial at HEP-DART 2025 - Business Wire
- 24 days ago - Precision BioSciences, Inc. (DTIL) Discusses ARCUS Platform Progress and ELIMINATE-B Clinical Trial Update for Chronic Hepatitis B Transcript - Seeking Alpha
- 25 days ago - Precision BioSciences Announces $75 Million Offering of Common Stock, Pre-Funded Warrants and Warrants - Business Wire
- 25 days ago - Precision BioSciences Presents Late-Breaking Phase 1 PBGENE-HBV Data at AASLD The Liver Meeting® Showing Safety, Tolerability and Cumulative, Dose-Dependent Antiviral Activity in First Three Cohorts - Business Wire
- 4 weeks ago - Precision BioSciences Reports Third Quarter 2025 Financial Results and Provides Business Update - Business Wire
- 5 weeks ago - Precision BioSciences to Report Third Quarter 2025 Financial Results on November 3, 2025 - Business Wire
- 7 weeks ago - Precision BioSciences Announces Late-Breaking Oral Presentation for PBGENE-HBV at AASLD The Liver Meeting® 2025 - Business Wire